Related Experiment Video

Updated: Apr 17, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Study Illuminates How Cancers Evade EGFR Inhibitors

    Cancer Discovery
    |February 15, 2015
    PubMed

    Insights

    Inactive epidermal growth factor receptor (EGFR) binds LAPTM4B in endosomes, initiating cancer-promoting autophagy. This interaction highlights a novel therapeutic target for cancer treatment.

    Area of Science:

    • Oncology
    • Cell Biology
    • Molecular Medicine

    Background:

    • Epidermal growth factor receptor (EGFR) is a key regulator of cell growth and survival.
    • Oncoproteins like LAPTM4B are frequently overexpressed in various cancers.
    • Autophagy is a cellular degradation process that can be hijacked by cancer cells for survival.

    Discussion:

    • This study reveals a novel interaction between inactive EGFR and LAPTM4B within endosomes.
    • The complex formed by EGFR and LAPTM4B actively induces autophagy, a survival mechanism in cancer cells.
    • This finding suggests that the EGFR-LAPTM4B complex plays a critical role in cancer progression.

    Key Insights:

    • Inactive EGFR forms a complex with the oncoprotein LAPTM4B in endosomes.
    • This complex triggers autophagy, a cytoprotective process that supports cancer cell survival.
    • The interaction identifies a new pathway for therapeutic intervention in cancer.

    Outlook:

    • Targeting the EGFR-LAPTM4B interaction could offer a novel strategy for cancer therapy.
    • Further research is needed to elucidate the precise mechanisms of autophagy induction by this complex.
    • Understanding this pathway may lead to the development of more effective anti-cancer drugs.

    More Related Videos

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    8.5K
    Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

    Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

    Published on: May 20, 2020

    9.5K

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.5K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    7.6K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    4.4K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.2K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    5.1K